HEM Pharma Inc. (KOSDAQ:376270)
South Korea · Delayed Price · Currency is KRW 33,900
0.00 (0.00%)
At close: Sep 18, 2026
HEM Pharma Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Cash & Equivalents | 7,555 | 13,785 | 6,274 |
Short-Term Investments | 2,000 | - | 5,000 |
Cash & Short-Term Investments | 9,555 | 13,785 | 11,274 |
Cash Growth | -9.78% | 22.27% | - |
Accounts Receivable | 1,758 | 1,655 | 4,371 |
Other Receivables | 190.92 | 46.01 | 65.79 |
Receivables | 2,096 | 1,708 | 4,437 |
Inventory | 5,733 | 1,505 | 975.27 |
Prepaid Expenses | 1,116 | 1,207 | 521.28 |
Other Current Assets | 4,817 | 4,430 | 98.49 |
Total Current Assets | 23,318 | 22,635 | 17,306 |
Property, Plant & Equipment | 29,027 | 26,116 | 17,628 |
Long-Term Investments | 1,589 | 573.29 | 46.75 |
Goodwill | 14.34 | 14.34 | - |
Other Intangible Assets | 1,605 | 1,443 | 793.74 |
Other Long-Term Assets | 1,233 | 1,052 | 1,087 |
Total Assets | 56,786 | 51,834 | 36,862 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Accounts Payable | 1,192 | 1,536 | 1,125 |
Accrued Expenses | 1,230 | 891.97 | 576.49 |
Short-Term Debt | 13,995 | 13,448 | 6,000 |
Current Portion of Long-Term Debt | 166.56 | 166.56 | 166.56 |
Current Portion of Leases | 466.06 | 444.19 | 316.2 |
Current Income Taxes Payable | - | 3.59 | - |
Other Current Liabilities | 18,149 | 23,996 | 892.18 |
Total Current Liabilities | 35,198 | 40,486 | 9,077 |
Long-Term Debt | 3,488 | 3,566 | 305.36 |
Long-Term Leases | 1,201 | 1,630 | 1,033 |
Pension & Post-Retirement Benefits | 278.45 | 614.23 | 68.25 |
Long-Term Deferred Tax Liabilities | - | 68.04 | - |
Other Long-Term Liabilities | 215.39 | 254.83 | 260.76 |
Total Liabilities | 40,381 | 46,619 | 10,744 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Common Stock | 3,605 | 3,579 | 3,481 |
Additional Paid-In Capital | 81,863 | 69,839 | 65,911 |
Retained Earnings | -78,543 | -75,874 | -51,864 |
Comprehensive Income & Other | 7,546 | 7,442 | 8,590 |
Total Common Equity | 14,471 | 4,986 | 26,118 |
Minority Interest | 1,748 | 228.45 | - |
Shareholders' Equity | 16,405 | 5,215 | 26,118 |
Total Liabilities & Equity | 56,786 | 51,834 | 36,862 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Total Debt | 19,316 | 19,255 | 7,821 |
Net Cash (Debt) | -9,761 | -5,470 | 3,453 |
Net Cash Growth | - | - | - |
Net Cash Per Share | -1368.20 | -777.61 | 543.32 |
Filing Date Shares Outstanding | 7.2 | 7.15 | 6.95 |
Total Common Shares Outstanding | 7.2 | 7.15 | 6.95 |
Working Capital | -11,880 | -17,851 | 8,229 |
Book Value Per Share | 2010.06 | 697.62 | 3756.88 |
Tangible Book Value | 12,851 | 3,529 | 25,324 |
Tangible Book Value Per Share | 1785.09 | 493.69 | 3642.70 |
Land | 7,213 | 7,213 | 6,936 |
Buildings | 5,939 | 5,939 | 3,510 |
Machinery | 13,508 | 10,137 | 8,636 |
Construction In Progress | 5,912 | 2,615 | 1,852 |